Sanofi Venetoclax: Breakthrough NK Cell Therapy Stuns at ASH 2023
Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study...
Merck, Eisai’s Shock: KEYTRUDA-LENVIMA Fail
Merck and Eisai have reported that the Phase 3 LEAP-001 trial for the first-line treatment of patients with advanced...
Pfizer Unveils Marstacimab: Hemophilia’s New Hope
Pfizer Inc. has shared promising results from its pivotal Phase 3 BASIS clinical trial of marstacimab, a potential new...
Merck Evobrutinib Fails in Trials: A Devastating Outcome for MS
Merck KGaA, a renowned science and technology company, has announced the results of its two Phase III EVOLUTION clinical...
BMS Opdivo Wins FDA Fast-Track: Remarkable Cancer Hope
Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review...
Pfizer New Diet Drug: Obsession for Healthy Change
Pfizer Inc., a renowned pharmaceutical company, has recently shared encouraging topline outcomes from their Phase 2b clinical trial. This...
PsychoGenics Revolutionary Brain Drug Set to Combat Mental Ills
PsychoGenics Inc., with its drug discovery platform PGI Drug Discovery LLC, has announced an exclusive license agreement with Roche...
JP Kotha Rises as VP of Bioanalytical at Worldwide Clinical Trials
Worldwide Clinical Trials, a significant contract research organization, has appointed Dr. Jayaprakash (JP) Kotha as Vice President, Bioanalytical. Dr....
Gilead Great Trodelvy Focus: New Insights
Gilead Sciences, Inc. is set to present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023, highlighting...
AstraZeneca’s ASH 2023: Surging Hematology Innovations
At the upcoming 65th American Society of Hematology (ASH) Annual Meeting, AstraZeneca will present a wealth of new clinical...